Beryl Drugs Ltd (BERLDRG) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Beryl Drugs Ltd on NSE and BSE, with an AI summary of each filing.
NON- APPLICABILITY CERTIFICATE UNDER REGULATION 57(5) FOR THE QUARTER ENDED 30.09.2026
Others (Uncategorized) · 08 Oct 2026, 12:14 am
Beryl Drugs Submits Regulatory Filings for Quarter Ended Sep'26 Beryl Drugs Limited has submitted quarterly compliance filings to BSE for the period ended 30th Sep'26. The company enclosed the certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, alongside a non-applicability certificate under Regulation 57(5) of SEBI LODR Regulations. Beryl Drugs confirmed that Regulation 57(5) is not applicable as it has no non-convertible securities with interest, dividend, or principal obligations payable during the quarter ended 30th Sep'26.
VOTING RESULTS OF 33RD ANNUAL GENERAL MEETING HELD ON 29TH SEPTEMBER, 2026
Annual General Meeting · 01 Oct 2026, 1:00 am
PROCEEDINGS OF 33RD ANNUAL GENERAL MEETING
Annual General Meeting · 29 Sept 2026, 8:03 pm
considered and approved the increase in limit of material related party transactions with M/S. AMINOVA INFUSIONS PVT. LTD.
Others (Uncategorized) · 29 Sept 2026, 5:22 pm
Beryl Drugs Approves Increased Related Party Transaction Limit with Aminova Infusions At its 33rd AGM on 29th Sep'26, Beryl Drugs Limited secured shareholder approval to increase the aggregate limit for material related party transactions with M/s Aminova Infusions Pvt. Ltd. from ₹5.00 crore to ₹8.00 crore. The revised ₹8.00 crore limit serves as the overall ceiling across the originally approved two-year tenure granted at the EGM on 11th May'26. All other terms, conditions, and transaction parameters remain unchanged, conducted in the ordinary course of business at arm's length.
OUTCOME OF 33RD ANNUAL GENERAL MEETING
Annual General Meeting · 29 Sept 2026, 5:05 pm
ANNUAL REPORT 2025-2026
Others (Uncategorized) · 04 Sept 2026, 12:06 am
33RD ANNUAL GENERAL MEETING NOTICE
Annual General Meeting · 03 Sept 2026, 9:33 pm
EVOTING DATES FOR THE PURPOSE OF 33RD ANNUAL GENERAL MEETING
Annual General Meeting · 03 Sept 2026, 5:32 am
RECORD DATE
Others · 03 Sept 2026, 5:30 am
Beryl Drugs Announces 33rd AGM, Book Closure, and E-voting Cut-off Dates Beryl Drugs Limited (BSE: 524606) announced its 33rd Annual General Meeting (AGM) will be held on 29th Sep'26. The board approved the annual book closure for equity shares from 23rd Sep'26 to 29th Sep'26 for the purpose of the AGM. Additionally, the company has fixed 22nd Sep'26 as the cut-off date to determine shareholder entitlements for remote e-voting rights.
OUTCOME OF BOARD MEETING
Outcome · 02 Sept 2026, 10:41 pm
Beryl Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/09/2026 ,inter alia, to consider and approve approve board report and other ....
Intimation · 28 Aug 2026, 3:15 am
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sudhir Sethi
Acquisition/ Disposal of Shares · 20 Aug 2026, 2:56 pm
Beryl Drugs Promoter Increases Stake Through Market Transaction Promoter Sudhir Sethi acquired 4,809 equity shares of Beryl Drugs Limited, representing 0.10% of the company's capital, via a market transaction on 18-Aug-26. Following the acquisition, his total shareholding has increased from 10.14% (514,119 shares) to 10.24% (518,928 shares). The company's total voting capital remains at 5,071,700 shares. This disclosure was made under SEBI's takeover regulations.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sudhir Sethi
Acquisition/ Disposal of Shares · 19 Aug 2026, 4:47 pm
Promoter Increases Stake in Beryl Drugs Promoter Sudhir Sethi acquired 3,000 equity shares (0.06% of capital) of Beryl Drugs Limited via a market transaction on 17-Aug-26. Following the acquisition, his total shareholding increased from 511,119 shares (10.08%) to 514,119 shares (10.14%). This disclosure was made under SEBI's takeover regulations. The company's total equity share capital remains unchanged at 50,71,700 shares.
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026
Financial Result · 11 Aug 2026, 10:45 pm
Beryl Drugs Q1FY27: Revenue Rises 57% YoY But Profit Slumps Sequentially Beryl Drugs reported a 57.0% YoY revenue increase to ₹756.63 lakhs for the quarter ended 30-Jun'26, driven by higher sales. However, revenues declined 38.4% QoQ. Net profit stood at ₹22.08 lakhs, a significant rise from ₹2.11 lakhs YoY, but a sharp 60.7% decrease QoQ from ₹56.25 lakhs in the prior quarter. This sequential profit drop was primarily due to a 58.6% QoQ increase in total expenses. Basic EPS for the quarter was ₹0.44, down from ₹1.11 in the preceding quarter but up from ₹0.04 YoY.
OUTCOME OF BOARD MEETING
Outcome · 11 Aug 2026, 10:36 pm
Beryl Drugs Board Approves Q1'FY27 Unaudited Financial Results Beryl Drugs Limited's board approved the unaudited financial results for the quarter ended 30th Jun'26 during its meeting on 11th Aug'26. The board also took on record the corresponding Limited Review Report from the auditors. The meeting confirmed the location for maintaining the company's books of accounts at its registered office in Indore.
Beryl Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve the unaudited financial results ....
Intimation · 11 Aug 2026, 5:30 am
Beryl Drugs Board Meeting on Aug 11 to Approve Q1FY27 Results Beryl Drugs Limited (BSE: 524606) has scheduled a Board of Directors meeting on 11th Aug'26 to consider and approve the Unaudited Financial Results for the quarter ended 30th Jun'26. The agenda also includes the adoption of the Limited Review Report for the same period. In line with SEBI regulations, the trading window, which closed on 1st Jul'26, will reopen 48 hours after the meeting's conclusion, on 13th Aug'26.
TEMPORARY UNAVAILABILITY OF THE COMPANY''S WEBSITE "www.beryldrugs.com" DUE TO AN UNEXPECTED TECHNICAL ISSUE.
Others (Uncategorized) · 21 Jul 2026, 6:35 pm
Beryl Drugs Reports Temporary Website Outage Due to Technical Issue Beryl Drugs Limited announced on 20 Jul'26 that its website, www.beryldrugs.com, is temporarily unavailable due to an unexpected technical issue. The company has initiated corrective measures and is working to restore normal operations at the earliest. Management confirmed that this temporary disruption affects only website accessibility and has no impact on business operations, financial systems, or statutory records. Beryl Drugs will provide further updates on the restoration as necessary under regulatory requirements.
NON-APPLOCABILITY CERTIFICATE UNDER REGULATION 57(5) FOR THE QUARTER ENDED 30TH JUNE, 2026
Others (Uncategorized) · 06 Jul 2026, 10:48 pm
Beryl Drugs Files Q1FY27 Compliance Reports with BSE Beryl Drugs Limited (BSE: 524606) submitted its mandatory compliance reports to the BSE for the quarter ended 30th Jun'26. The submission, dated 06th Jul'26, includes the certificate under Regulation 74(5) concerning depositories. Additionally, the company filed a non-applicability certificate for Regulation 57(5), confirming it has no non-convertible securities with interest, dividend, or principal payments due during the quarter. This indicates no obligation related to listed debt securities for the period.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sudhir Sethi
Acquisition/ Disposal of Shares · 29 Jun 2026, 6:32 pm
Beryl Drugs Promoter Sudhir Sethi Increases Stake in Company Promoter Sudhir Sethi acquired 6,950 shares (0.13% stake) in Beryl Drugs Ltd via market transactions on 25-Jun-26. This acquisition increases his total holding in the company from 504,169 shares (9.915%) to 511,119 shares (10.055%). The company's total equity share capital remains at 50,71,700 shares post-transaction. This move signals increased promoter confidence in the company. The disclosure was filed under SEBI's substantial acquisition regulations.
CHANGE IN REGISTERED OFFICE OF THE COMPANY FROM 133, KANCHAN BAGH, INDORE TO 29, NEER NAGAR, MAYANK WATER PARK ROAD, BICHOLI, INDORE WITHIN LOCAL LIMITS OF SAME CITY
Others (Uncategorized) · 16 Jun 2026, 8:43 pm
Beryl Drugs Announces Change of Registered Office in Indore Beryl Drugs (BSE: 524606) announced its Board of Directors approved a change in the company's registered office on 16th Jun'26. Effective 1st Jul'26, the office will move from 133, Kanchan Bagh, Indore-452001 to 29, Neer Nagar, Mayank Water Park Road, Bicholi, Indore-452016. The relocation, cited for administrative convenience, is within the same city and local limits. The company's Corporate Identification Number (CIN) remains unchanged.
OUTCOME OF BOARD MEETING
Outcome · 16 Jun 2026, 8:36 pm
Beryl Drugs Approves Registered Office Relocation Within Indore Beryl Drugs announced its Board of Directors approved shifting the company's registered office in a meeting held on 16th Jun'26. The office will relocate within the local limits of Indore, moving from 133, Kanchan Bagh, Indore-452001 to 29, Neer Nagar, Mayank Water Park Road, Bicholi, Indore-452016.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sudhir Sethi
Acquisition/ Disposal of Shares · 12 Jun 2026, 11:05 pm
Beryl Drugs Promoter Sudhir Sethi Increases Shareholding Beryl Drugs promoter Sudhir Sethi acquired 30 additional equity shares via an open market transaction on 10-Jun-26. This purchase represents 0.005% of the company's total share capital. Following the acquisition, Sethi's total holding increased from 504,139 shares (9.85% stake) to 504,169 shares, raising his stake to 9.915% of the company's total voting capital. The company's total equity share capital remains unchanged at 50,71,700 shares.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sudhir Sethi
Acquisition/ Disposal of Shares · 11 Jun 2026, 3:56 pm
Beryl Drugs: Promoter Sudhir Sethi Increases Stake Through Market Transaction Promoter Sudhir Sethi acquired 3,482 equity shares (0.06% of total capital) of Beryl Drugs via a market transaction on 09-Jun-26. Following the acquisition, his total shareholding increased from 500,657 shares (9.85%) to 504,139 shares (9.91%). The company's total equity share capital remains unchanged at 50,71,700 shares post-transaction. This disclosure was made under SEBI's SAST Regulations, 2011.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sudhir Sethi
Acquisition/ Disposal of Shares · 10 Jun 2026, 3:42 pm
Beryl Drugs Promoter Increases Stake in Company Beryl Drugs promoter, Mr. Sudhir Sethi, acquired 4,682 equity shares via a market transaction on 8-Jun'26, representing 0.1% of the company's total share capital. Following the acquisition, his total shareholding increased from 495,975 shares (9.75%) to 500,657 shares (9.85%). The company's total equity share capital remains unchanged at 5,071,700 shares. This disclosure was made under Regulation 29(2) of SEBI's SAST Regulations, 2011.
Beryl Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/06/2026 ,inter alia, to consider and approve change in registered office of ....
Intimation · 09 Jun 2026, 12:24 am
Beryl Drugs to Consider Registered Office Relocation at Jun'26 Board Meeting Beryl Drugs Ltd. (BSE: 524606) has scheduled a Board of Directors meeting for 16th Jun'26. The primary agenda item is to consider and approve the change of its registered office location. The proposed relocation is within the local limits of Indore, moving from 133, Kanchan Bagh, Indore-452001 to 29, Neer Nagar, Mayank Water Park Road, Bicholi, Indore-452016.